Current Edition


RadioMedix, Areva Med begin phase 1 trial of AlphaMedix to treat neuroendocrine tumours

RadioMedix,a clinical stage biotechnology company, and Areva Med, a nuclear biotech company, have announced the initiation in the United States of phase 1 trial for …

Continue Reading →

GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-reviewed articles have been published …

Continue Reading →

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. …

Continue Reading →